LabGenius Therapeutics

📍 London, United Kingdom🗓 Founded 2012👥 72 employees💰 Last funded Feb 2026
Biotechnology Research🌐 labgeniustx.com
Website LinkedIn
LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVA™ is both modality and format-agnostic, LabGenius internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The companys novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.
4
Total investors
0
Early stage
1
Mid stage
1
Late stage
2012
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
4
Investor activity2017–2026 · investors recorded per year
20171202112024120261
Recent (last 2y)Earlier
Frequently asked questions
Who invested in LabGenius Therapeutics?
LabGenius Therapeutics has 4 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did LabGenius Therapeutics last raise funding?
The most recent investment in LabGenius Therapeutics recorded on gritt.io was in February 2026.
When was LabGenius Therapeutics founded?
LabGenius Therapeutics was founded in 2012.
What industry is LabGenius Therapeutics in?
LabGenius Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is LabGenius Therapeutics based?
LabGenius Therapeutics is headquartered in London, United Kingdom.